Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 2No longer available 1Completed 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 2Observational 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 4Adenocarcinoma of Lung 2Sarcoma 1Neoplasm Metastasis 1Carcinoma 1Bronchial Neoplasms 1

Interventions

Specimen Handling 51Carboplatin 49pembrolizumab 45Magnetic Resonance Spectroscopy 43Pemetrexed 39Cisplatin 34Paclitaxel 24durvalumab 23osimertinib 20Nivolumab 19Gemcitabine 19Radiosurgery 17Docetaxel 17atezolizumab 14Taxes 12Radiotherapy 12Immunoglobulin G 12Disulfides 12130-nm albumin-bound paclitaxel 12Etoposide 11Educational Status 11Biopsy 11Radiation 10Drug Therapy 10Blood Specimen Collection 10Platinum 9Early Intervention, Educational 9Cetuximab 9Methods 8Bevacizumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lung Neoplasms × capmatinib × 90 days × Clear all
NCT05642572 2026-06-03

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Recruiting
66 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05703516 2026-06-01

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Novartis

Recruiting
44 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05110196 2026-04-07

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Novartis

Phase 4 Completed
50 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04741789 2026-03-16

Managed Access Programs for INC280, Capmatinib

Novartis

No longer available
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡